东亚药业(605177.SH)公告称，公司收到韩国食品药品监督管理局（韩国MFDS）原料药品注册证书，产 品名称为曲美布汀，DMF注册号为20250509-13-B-489-16。曲美布汀具有调节胃肠道运动功能紊乱的作 用，2024年度马来酸曲美布汀制剂全国销售额约为3.72亿元。该证书的获得将有助于公司拓展韩国医药 市场，并可能促进曲美布汀原料药在其他海外市场的销售。但需注意海外市场政策环境变化和 汇率波 动等因素的影响。 ...

浙江东亚药业股份有限公司 2024 年年度股东大会会议资料 证券代码：605177 证券简称：东亚药业 债券代码：111015 债券简称：东亚转债 浙江东亚药业股份有限公司 2024 年年度股东大会 会议资料 二〇二五年五月 | . | . | | | | --- | --- | --- | --- | | 1 4 | 13.0 | 1 | A | | 2024 | 年年度股东大会会议须知 1 | | | --- | --- | --- | | 2024 | 年年度股东大会会议议程 2 | | | 2024 | 年年度股东大会会议议案 4 | | | 议案 | 1： | 4 | | 关于 | 2024 年度董事会工作报告的议案 4 | | | 议案 | 2： 20 | | | 关于 | 2024 年度监事会工作报告的议案 20 | | | 议案 | 3： 25 | | | 关于 | 2024 年度独立董事履职情况报告的议案 25 | | | 议案 | 4： 26 | | | 关于 | 2024 年度财务决算报告的议案 26 | | | 议案 | 5： 34 | | | 关于 | 2024 年年度报告及其摘要的 ...

浙江东亚药业股份有限公司 关于举办2024年度暨2025年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | 证券代码：605177 | 证券简称：东亚药业 | 公告编号：2025-025 | | --- | --- | --- | | 债券代码：111015 | 债券简称：东亚转债 | | 一、说明会类型 公司已于 2025 年 4 月 30 日在上海证券交易所网站（www.sse.com.cn）披露 了《2024 年年度报告》、《2024 年年度报告摘要》及《2024 年第一季度报告》。 为便于广大投资者更加全面深入地了解公司经营业绩、发展战略等情况，公司定 于 2025 年 5 月 20 日（星期二）10:30-11:30 在"价值在线"（www.ir-online.cn） 举办东亚药业（605177）2024 年度暨 2025 年第一季度业绩说明会，与投资者进 会议召开时间：2025 年 5 月 20 日（星期二）10:30-11:30 会议召开方式：视频结合网络文字互动方式 会议召开地点：价 ...

东兴证券股份有限公司(以下简称"东兴证券"或"保荐机构")作为东亚 药业本次发行的保荐机构,持续督导期自 2023年 8 月 2 日至 2024 年 12 月 31 日,目前持续督导期已满,根据《证券发行上市保荐业务管理办法》、《上海证券 交易所上市公司自律监管指引第 11 号—持续督导》等有关法律法规和规范性文 件的要求,出具持续督导保荐总结报告书。 一、保荐机构及保荐代表人承诺 1、保荐总结报告书和证明文件及其相关资料的内容不存在虚假记载、误导 性陈述或重大遗漏,保荐机构及保荐代表人对其真实性、准确性、完整性承担法 律责任。 2、保荐机构及保荐代表人自愿接受中国证监会对保荐总结报告书相关事项 进行的任何质询和调查。 3、保荐机构及保荐代表人自愿接受中国证监会、上海证券交易所按照《证 券发行上市保荐业务管理办法》等有关规定采取的监管措施。 二、保荐机构基本情况 车兴证券股份有限公司关于 浙江东亚药业股份有限公司 向不特定对象发行可转换公司债券之保荐总结报告书 根据中国证券监督管理委员会《关于同意浙江东亚药业股份有限公司向不特 定对象发行可转换公司债券注册的批复》(证监许可（2023）1165 号),公司获 ...

东亚药业发行费用合计1.02亿元，其中，保荐机构东兴证券股份有限公司获得保荐及承销费用6143.87万 元。 据公司4月30日披露的《东兴证券股份有限公司关于浙江东亚药业股份有限公司2024年度募集资金存放 与使用情况专项核查报告》，根据中国证监会批复(证监许可〔2023〕1165号)，公司获准向不特定对象 | 项目 | 本报告期 | 上年同期 | 本报告期比上年同期增 | | --- | --- | --- | --- | | | | | 减变动幅度(%) | | 营业收入 | 190, 921, 213. 83 | 352. 582. 674. 10 | -45. 85 | | 归属于上市公司股东的净 | -6, 919, 576. 54 | 24, 039, 198. 04 | -128.78 | | 利润 | | | | | 归属于上市公司股东的扣 | -10, 505, 893. 27 | 20, 376, 579. 89 | -151. 56 | | 除非经常性损益的净利润 | | | | | 经营活动产生的现金流量 | -134, 527, 926. 86 | -97, 089, 771. 88 ...

Core Viewpoint - The company, Zhejiang Dongya Pharmaceutical Co., Ltd., reported a decrease in revenue and net profit for the year 2024, indicating challenges in its financial performance amidst a growing pharmaceutical market. Company Overview - Zhejiang Dongya Pharmaceutical operates in the pharmaceutical manufacturing industry, specifically in the chemical pharmaceutical sector, which is positioned in the midstream of the overall pharmaceutical industry chain [6][19]. Market Overview - The global pharmaceutical market is projected to grow from $1,557.2 billion in 2023 to $1,638.7 billion in 2024, driven by factors such as population changes and advancements in artificial intelligence [7]. - China's pharmaceutical market is expected to expand from ¥179.77 billion in 2023 to ¥193.12 billion in 2024, with a forecast to exceed ¥2 trillion by 2025 [9]. Chemical Raw Material Market - The global raw material pharmaceutical market is anticipated to reach $226.1 billion by 2024, with a compound annual growth rate (CAGR) of 6% from 2023 to 2032 [10]. - China has become the world's largest producer and exporter of raw materials, with its production capacity increasing from approximately 9.3% in 2008 to about 30% in 2022 [11]. Company Financial Performance - For the reporting period, the company achieved revenue of ¥1,198.24 million, a decrease of 11.66% year-on-year, and a net profit attributable to shareholders of -¥100.66 million, down 183.02% year-on-year [27]. Product Positioning - The company has established a competitive advantage in the production of β-lactam antibiotics and quinolone antibiotics, with significant market presence in the production of key intermediates [17][19]. - The company is actively expanding its product offerings into the fields of cephalosporin antibiotics and is enhancing its production capabilities to meet downstream demand [18]. Business Strategy - The company is pursuing a strategy of integrating raw material and formulation production to enhance market opportunities and improve cost efficiency [12][19]. - The company has established a comprehensive supply chain management system to ensure stable supply and quality of raw materials [20]. Regulatory Environment - The Chinese government has implemented policies to support the development of innovative drugs and improve the overall quality of pharmaceuticals, which is expected to benefit leading companies in the raw material sector [11][14].

Core Viewpoint - Zhejiang Dongya Pharmaceutical Co., Ltd. faces significant challenges in 2024, with key financial indicators showing substantial changes, including a 183.02% decrease in net profit and a 43.16% increase in R&D expenses, which warrant close attention from investors [1]. Revenue - In 2024, the company achieved operating revenue of 1,198,238,535.39 yuan, a decrease of 11.66% from 1,356,448,097.16 yuan in the previous year, primarily due to fluctuating market demand [2]. - Quarterly revenue showed a downward trend, with figures of 352,582,674.10 yuan, 295,643,846.05 yuan, 314,792,722.32 yuan, and 235,219,292.92 yuan from Q1 to Q4, indicating pressure in market expansion [2]. Net Profit - The net profit attributable to shareholders was -100,660,051.84 yuan, down 183.02% from 121,249,399.50 yuan in 2023, attributed to reduced revenue, increased asset impairment losses, and higher R&D expenses [3]. - The company recognized inventory impairment losses due to operational management conditions and market changes, while the increase in R&D expenses was aimed at advancing the integrated development strategy of raw material drugs [3]. Deducted Net Profit - The deducted net profit was -98,408,150.01 yuan, a 191.03% decrease from 108,102,069.34 yuan in 2023, highlighting severe impacts on the core business's profitability [4]. - The minimal impact of non-recurring gains and losses on net profit indicates a need for improved competitiveness and cost control in core operations [4]. Earnings Per Share - Basic earnings per share were -0.90 yuan, down 184.11% from 1.07 yuan in 2023, reflecting a significant decline in the company's ability to create value for shareholders [5]. - The deducted earnings per share were -0.88 yuan, a 192.63% decrease from 0.95 yuan in 2023, consistent with the trends in deducted net profit, indicating a need for a reassessment of core business strategies [6]. Expenses - Overall expenses increased, with sales expenses rising by 11.29% to 15,387,268.47 yuan, management expenses up 24.14% to 170,269,093.67 yuan, and R&D expenses increasing by 43.16% to 117,016,684.56 yuan, reflecting pressure on cost control [7]. - Financial expenses decreased to -5,991,571.27 yuan from -7,909,974.75 yuan, indicating changes in cash flow management [7]. R&D Investment and Personnel - R&D investment reached 138,875,057.98 yuan, accounting for 11.59% of operating revenue, with a capitalized ratio of 15.74%, demonstrating a commitment to innovation [8]. - The R&D team consisted of 155 personnel, with a significant proportion being young and educated, although there may be a need for more high-end talent [9]. Cash Flow - The net cash flow from operating activities was -156,549,765.40 yuan, worsening from -84,061,904.21 yuan in the previous year, indicating increased cash outflow pressures [10]. - Investment activities resulted in a net cash flow of -90,159,116.32 yuan, while financing activities saw a significant decrease of 94.89% to 31,539,308.19 yuan, primarily due to the absence of large-scale fundraising in 2024 [10].

Core Insights - The company reported a net loss of approximately 101 million yuan for the fiscal year 2024, with total revenue of 1.198 billion yuan, reflecting a slight year-on-year decline [1] - The primary reason for the loss was asset impairment due to inventory write-downs and contract performance cost reductions, leading to a one-time asset impairment provision of 145 million yuan [1] - Despite poor financial performance, the company is advancing its capacity construction and R&D efforts, which are expected to enhance its core competitiveness in the long run [1][4] Financial Performance - The company’s revenue for 2024 was 1.198 billion yuan, a slight decrease compared to the previous year [1] - The first quarter of 2025 also showed continued losses, indicating ongoing financial challenges [1] - R&D investment reached a record high of 139 million yuan, accounting for 11.59% of total revenue, marking a 69.14% increase year-on-year [4] Product and Market Development - Key products maintained growth, with sales of the core product, Cefaclor, increasing by 28.24% for raw materials and 15.56% for intermediates in 2024 [2] - The company achieved a 11.55% increase in overseas revenue, totaling 209 million yuan, which supports its resilience against domestic healthcare cost controls [2] - The company received several international certifications for its raw materials, including WHO PQ certification for Levofloxacin, enhancing its global market competitiveness [3] Strategic Initiatives - The company is focused on a strategy of "forward extension and backward extension," emphasizing raw materials and expanding its product pipeline [4][5] - The completion of a convertible bond issuance raised nearly 700 million yuan, which is being used to expand production capacity and enhance product offerings [5] - The company is making significant progress in its formulation business, with multiple product registration applications submitted, indicating a robust pipeline for future growth [6]

| 证券代码：605177 | 证券简称：东亚药业 | 公告编号：2025-024 | | --- | --- | --- | | 债券代码：111015 | 债券简称：东亚转债 | | 浙江东亚药业股份有限公司 关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 召开的日期时间：2025 年 5 月 20 日 14 点 00 分 召开地点：浙江省台州市临海市台州湾经济技术开发区东海第五大道 21 号 股东大会召开日期：2025年5月20日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 二楼会议室五 (五)网络投票的系统、起止日期和投票时间。 一、 召开会议的基本情况 (一)股东大会类型和届次 2024年年度股东大会 (二)股东大会召集人：董事会 (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的 方式 (四)现场会议召开的日期、时间和地点 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 5 月 ...

| 证券代码：605177 | 证券简称：东亚药业 | 公告编号：2025-015 | | --- | --- | --- | | 债券代码：111015 | 债券简称：东亚转债 | | 浙江东亚药业股份有限公司 第四届监事会第六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 浙江东亚药业股份有限公司（以下简称"公司"）第四届监事会第六次会议于 2025 年 4 月 28 日（星期一）在浙江省台州市临海市台州湾经济技术开发区东海第五大道 21 号二楼会议室五以现场表决的方式召开，本次会议通知已于 2025 年 4 月 18 日通过邮件 的方式送达公司全体监事。 本次会议由监事会主席徐菁女士主持，会议应参加表决监事 3 人，实际参加表决 监事 3 人。本次会议的召集、召开符合《中华人民共和国公司法》等法律、法规和 《公司章程》的有关规定。 二、监事会会议审议情况 （一）审议通过《关于 2024 年度监事会工作报告的议案》 表决情况：同意 3 票，反对 0 票，弃权 0 票。 本议案尚需提交股东 ...